Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

被引:617
作者
Maini, R. N. [1 ]
Taylor, P. C.
Szechinski, J.
Pavelka, K.
Broell, J.
Balint, G.
Emery, P.
Raemen, F.
Petersen, J.
Smolen, J.
Thomson, D.
Kishimoto, T.
机构
[1] Univ London Imperial Coll Sci & Technol, Kennedy Inst Rheumatol, London W6 8LH, England
[2] Univ Sch Wroclaw, Wroclaw, Poland
[3] Inst Rheumatol, Prague, Czech Republic
[4] Ludwig Boltzmann Inst Rheumatol & Balneol, Vienna, Austria
[5] Natl Inst Rheumatism & Physiotherapy, Budapest, Hungary
[6] Univ Leeds, Leeds, W Yorkshire, England
[7] AZ Jan Palfijn Hosp, Antwerp, Belgium
[8] State Univ Hosp, Finsen Ctr, Copenhagen, Denmark
[9] Med Univ Vienna, Vienna, Austria
[10] Lainz Hosp, Vienna, Austria
[11] Chugai Pharma Europe, London, England
[12] Osaka Univ, Osaka, Japan
来源
ARTHRITIS AND RHEUMATISM | 2006年 / 54卷 / 09期
关键词
D O I
10.1002/art.22033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To establish the safety and efficacy of repeat infusions of tocilizumab (previously known as MRA), a humanized anti-interleukin-6 (IL-6) receptor antibody, alone and in combination with methotrexate (MTX), for the treatment of rheumatoid arthritis (RA). Methods. The study group comprised 359 patients with active RA in whom the response to MTX was inadequate. During a stabilization period, these patients received their current dose of MTX for at least 4 weeks. Following stabilization, they were randomized to I of 7 treatment arms, as follows: tocilizumab at doses of 2 mg/kg, 4 mg/kg, or 8 mg/kg either as monotherapy or in combination with MTX, or MTX plus placebo. Results. A 20% response (improvement) according to the American College of Rheumatology criteria (ACR20 response) was achieved by 61% and 63% of patients receiving 4 mg/kg and 8 mg/kg of tocilizumab as monotherapy, respectively, and by 63% and 74% of patients receiving those doses of tocilizumab plus MTX, respectively, compared with 41% of patients receiving placebo plus MTX. Statistically significant ACR50 and ACR70 responses were observed in patients receiving combination therapy with either 4 mg/kg or 8 mg/kg of tocilizumab plus MTX (P < 0.05). A dose-related reduction in the Disease Activity Score in 28 joints was observed from week 4 onward, in all patients except those receiving monotherapy with 2 mg/kg of tocilizumab. In the majority of patients who received 8 mg/kg of tocilizumab, the C-reactive protein level/erythrocyte sedimentation rate normalized, while placebo plus MTX had little effect on these laboratory parameters. Tocilizumab was mostly well tolerated, with a safety profile similar to that of other biologic and immunosuppressive therapies. Alanine transaminase and aspartate transaminase levels followed a sawtooth pattern (rising and falling between infusions). There were moderate but reversible increases in the nonfasting total cholesterol and triglyceride levels and reversible reductions in the high-density lipoprotein cholesterol and neutrophil levels. There were 2 cases of sepsis, both of which occurred in patients who were receiving combination therapy with 8 mg/kg of tocilizumab plus MTX. Conclusion. These results indicate that targeted blockade of IL-6 signaling is a highly efficacious and promising means of decreasing disease activity in RA.
引用
收藏
页码:2817 / 2829
页数:13
相关论文
共 37 条
[1]   Interleukin 6 is required for the development of collagen-induced arthritis [J].
Alonzi, T ;
Fattori, E ;
Lazzaro, D ;
Costa, P ;
Probert, L ;
Kollias, G ;
De Benedetti, F ;
Poli, V ;
Ciliberto, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (04) :461-468
[2]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[3]   Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis [J].
Boe, A ;
Baiocchi, M ;
Carbonatto, M ;
Papoian, R ;
Serlupi-Crescenzi, O .
CYTOKINE, 1999, 11 (12) :1057-1064
[4]   Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial [J].
Choy, EHS ;
Isenberg, DA ;
Garrood, T ;
Farrow, S ;
Ioannou, Y ;
Bird, H ;
Cheung, N ;
Williams, B ;
Hazleman, B ;
Price, R ;
Yoshizaki, K ;
Nishimoto, N ;
Kishimoto, T ;
Panayi, GS .
ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3143-3150
[5]   Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis [J].
de Hooge, ASK ;
van de Loo, FAJ ;
Arntz, OJ ;
van den Berg, WB .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (06) :2081-2091
[6]   Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis:: serum levels and relationship to inflammation [J].
Dursunoglu, D ;
Evrengül, H ;
Polat, B ;
Tanriverdi, H ;
Çobankara, V ;
Kaftan, A ;
Kiliç, M .
RHEUMATOLOGY INTERNATIONAL, 2005, 25 (04) :241-245
[7]   Anti-TNFα therapy of rheumatoid arthritis:: what have we learned? [J].
Feldmann, M ;
Maini, RN .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :163-196
[8]   AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY DEFINITION OF IMPROVEMENT IN RHEUMATOID-ARTHRITIS [J].
FELSON, DT ;
ANDERSON, JJ ;
BOERS, M ;
BOMBARDIER, C ;
FURST, D ;
GOLDSMITH, C ;
KATZ, LM ;
LIGHTFOOT, R ;
PAULUS, H ;
STRAND, V ;
TUGWELL, P ;
WEINBLATT, M ;
WILLIAMS, HJ ;
WOLFE, F ;
KIESZAK, S .
ARTHRITIS AND RHEUMATISM, 1995, 38 (06) :727-735
[9]   INTERFERON BETA-2/B-CELL STIMULATORY FACTOR TYPE-2 SHARES IDENTITY WITH MONOCYTE-DERIVED HEPATOCYTE-STIMULATING FACTOR AND REGULATES THE MAJOR ACUTE PHASE PROTEIN RESPONSE IN LIVER-CELLS [J].
GAULDIE, J ;
RICHARDS, C ;
HARNISH, D ;
LANSDORP, P ;
BAUMANN, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (20) :7251-7255
[10]   SYNOVIUM AS A SOURCE OF INTERLEUKIN 6 INVITRO - CONTRIBUTION TO LOCAL AND SYSTEMIC MANIFESTATIONS OF ARTHRITIS [J].
GUERNE, PA ;
ZURAW, BL ;
VAUGHAN, JH ;
CARSON, DA ;
LOTZ, M .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (02) :585-592